From Nasdaq:

Ark Invest CEO/CIO Cathie Wood invests in disruptive technologies through her company’s family of ETFs, including the flagship fund ARKK. Wood holds a significant position in CRISPR Therapeutics, which recently achieved approval for a gene therapy. Analysts expect eventual sales to reach $1 billion per year before 2030, and CRISPR is developing a pipeline of candidates for other high-value indications. Despite potential for slow initial sales, the long-term prospects for CRISPR are bright. Investors should consider this biotech stock a strong buy for the future.



Read more: 1 Cathie Wood Stock Worth Buying Hand Over Fist in 2024